Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.

Kwa M, Li X, Novik Y, Oratz R, Jhaveri K, Wu J, Gu P, Meyers M, Muggia F, Speyer J, Iwano A, Bonakdar M, Kozhaya L, Tavukcuoglu E, Budan B, Raad R, Goldberg JD, Unutmaz D, Adams S.

Breast Cancer Res Treat. 2018 Feb;168(1):57-67. doi: 10.1007/s10549-017-4570-4. Epub 2017 Nov 9.

PMID:
29124456
2.

Generation of a SOX2 reporter human induced pluripotent stem cell line using CRISPR/SaCas9.

Balboa D, Weltner J, Novik Y, Eurola S, Wartiovaara K, Otonkoski T.

Stem Cell Res. 2017 Jul;22:16-19. doi: 10.1016/j.scr.2017.05.005. Epub 2017 May 17.

3.

Generation of an OCT4 reporter human induced pluripotent stem cell line using CRISPR/SpCas9.

Balboa D, Weltner J, Novik Y, Eurola S, Wartiovaara K, Otonkoski T.

Stem Cell Res. 2017 Aug;23:105-108. doi: 10.1016/j.scr.2017.07.006. Epub 2017 Jul 11.

4.

Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.

Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D.

NPJ Breast Cancer. 2016 Dec 14;2:16037. doi: 10.1038/npjbcancer.2016.37. eCollection 2016.

5.

Results of a phase I-II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer.

Formenti SC, Golden EB, Goldberg JD, Li X, Taff J, Fenton-Kerimian MB, Chandrasekhar S, Demaria S, Novik Y.

Oncoimmunology. 2016 Dec 27;6(3):e1274479. doi: 10.1080/2162402X.2016.1274479. eCollection 2017.

6.

[EXPRESSION OF PFKFB, HK2, NAMPT, TSPAN13 AND HSPB8 GENES IN PEDIATRIC GLIOMA].

Minchenko DO, Novik YE, Maslak HS, Tiazhka OV, Minchenko OH.

Lik Sprava. 2015 Oct-Dec;(7-8):43-8. Ukrainian.

PMID:
27491149
7.

Clinical trial evidence of the antitumor activity of topical imiquimod for breast cancer skin metastases.

Adams S, Novik Y, Oratz R, Axelrod D, Speyer J, Tiersten A, Goldberg JD, Bhardwaj N, Unutmaz D, Demaria S, Formenti S.

J Clin Oncol. 2014 Oct 1;32(28):3204-5. doi: 10.1200/JCO.2014.56.1282. Epub 2014 Aug 4. No abstract available.

PMID:
25092780
8.

Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer.

Singh J, Novik Y, Stein S, Volm M, Meyers M, Smith J, Omene C, Speyer J, Schneider R, Jhaveri K, Formenti S, Kyriakou V, Joseph B, Goldberg JD, Li X, Adams S, Tiersten A.

Breast Cancer Res. 2014 Mar 31;16(2):R32. doi: 10.1186/bcr3634.

9.

Role of HER2 status in the treatment for brain metastases arising from breast cancer with stereotactic radiosurgery.

Tam M, Narayana A, Raza S, Kunnakkat S, Golfinos JG, Parker EC, Novik Y.

Med Oncol. 2014 Feb;31(2):832. doi: 10.1007/s12032-013-0832-0. Epub 2014 Jan 5.

PMID:
24390418
10.

Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer.

Adams S, Kozhaya L, Martiniuk F, Meng TC, Chiriboga L, Liebes L, Hochman T, Shuman N, Axelrod D, Speyer J, Novik Y, Tiersten A, Goldberg JD, Formenti SC, Bhardwaj N, Unutmaz D, Demaria S.

Clin Cancer Res. 2012 Dec 15;18(24):6748-57. doi: 10.1158/1078-0432.CCR-12-1149. Epub 2012 Jul 5.

11.

Phase II Evaluation of Liposomal Doxorubicin with Docetaxel in Patients with Metastatic Breast Cancer.

Fasano J, Hershman D, Novik Y, Levinson B, Blozie K, Tiersten AD.

Breast Care (Basel). 2010 Mar;5(1):17-21. Epub 2010 Feb 2.

12.
13.

Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia.

Karbasian-Esfahani M, Wiernik PH, Novik Y, Paietta E, Dutcher JP.

Cancer. 2004 Sep 15;101(6):1414-9.

14.

Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer.

Raff JP, Rajdev L, Malik U, Novik Y, Manalo JM, Negassa A, Hopkins U, Sarta C, Sparano JA.

Clin Breast Cancer. 2004 Feb;4(6):420-7.

PMID:
15023243
15.

Presence of ADAMTS13 activity in a patient with metastatic cancer and thrombotic microangiopathy.

Forman RB, Benkel SA, Novik Y, Tsai HM.

Acta Haematol. 2003;109(3):150-2.

PMID:
12714826
16.

20th-century advances in drug therapy in oncology--Part. II.

Dutcher JP, Novik Y, O'Boyle K, Marcoullis G, Secco C, Wiernik PH.

J Clin Pharmacol. 2000 Oct;40(10):1079-92. Review.

PMID:
11028247
17.

20th-century advances in drug therapy in oncology--Part I.

Dutcher JP, Novik Y, O'Boyle K, Marcoullis G, Secco C, Wiernik PH.

J Clin Pharmacol. 2000 Sep;40(9):1007-24. No abstract available.

PMID:
10975071
18.

Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282.

Novik Y, Ryan LM, Haller DG, Asbury R, Dutcher JP, Schutt A.

Med Oncol. 1999 Dec;16(4):261-6.

PMID:
10618689
19.

Therapeutic efficacy of theophylline in chronic lymphocytic leukemia.

Makower D, Malik U, Novik Y, Wiernik PH.

Med Oncol. 1999 Apr;16(1):69-71.

PMID:
10382946
20.

Successful treatment of a patient on adrenal steroid replacement therapy with high-dose bolus interleukin-2 for metastatic renal cell carcinoma.

Deshpande H, Dutcher JP, Novik Y, Oleksowicz L.

Cancer J Sci Am. 1999 Jan-Feb;5(1):52-3. No abstract available.

PMID:
10188062
21.

Familial erythroleukemia: a distinct clinical and genetic type of familial leukemias.

Novik Y, Marino P, Makower DF, Wiernik PH.

Leuk Lymphoma. 1998 Jul;30(3-4):395-401. Review.

PMID:
9713970
22.

Supplemental Content

Support Center